Alexander Fossa

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 95 publications

Erratum to: "A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma".

Erratum to: "A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma".

Journal: Haematologica
Published: August 01, 2026

Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non-Hodgkin Lymphoma on Reproduction Patterns.

Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non-Hodgkin Lymphoma on Reproduction Patterns.

Journal: European journal of haematology
Published: May 14, 2026

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

Journal: HemaSphere
Published: April 14, 2026

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

Journal: HemaSphere
Published: March 25, 2026

Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional survey.

Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional survey.

Journal: Leukemia & lymphoma
Published: February 28, 2026

Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access.

Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access.

Journal: British journal of haematology
Published: February 27, 2026

Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma.

Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma.

Journal: Blood advances
Published: January 13, 2026

A Phase II Study of 177Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients.

A Phase II Study of 177Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 01, 2025

AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.

AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.

Journal: Blood advances
Published: October 31, 2025

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 17, 2025

Response to Comment on: "A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma".

Response to Comment on: "A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma".

Journal: Haematologica
Published: May 25, 2025

Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients.

Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients.

Journal: HemaSphere
Published: April 14, 2025
Showing 1-12 of 95

Last Updated: 09/26/2026